Earnings summaries and quarterly performance for ABVC BIOPHARMA.
Executive leadership at ABVC BIOPHARMA.
Board of directors at ABVC BIOPHARMA.
CJ
Chang-Jen Jiang
Detailed
Director
CH
Che-Wei Hsu
Detailed
Independent Director
HM
Hsin-Hui Miao
Detailed
Independent Director
NS
Norimi Sakamoto
Detailed
Independent Director
SJ
Shuling Jiang
Detailed
Director
TM
Tsang Ming Jiang
Detailed
Director
YC
Yen-Hsin Chou
Detailed
Independent Director
YO
Yoshinobu Odaira
Detailed
Independent Director
YC
Yu-Min Chung
Detailed
Independent Director
Research analysts covering ABVC BIOPHARMA.
Recent press releases and 8-K filings for ABVC.
ABVC BioPharma Reports Q3 2025 Financial Results
ABVC
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- ABVC BioPharma reported licensing revenue of approximately USD 1.28 million for Q3 2025, representing a 230% year-over-year increase compared to the same period in 2024.
- Total assets for the company reached USD 21.18 million as of September 30, 2025, an increase of approximately 181% from USD 7.54 million at December 31, 2024.
- Property and equipment (net) totaled USD 12.06 million, reflecting a 2,100% growth from USD 0.51 million at the end of 2024, primarily due to USD 11 million in recent real-asset investments in Taiwan for a plant factory and agricultural R&D.
Nov 3, 2025, 12:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more